E
Amicus Therapeutics, Inc.
FOLD
$6.53
-$0.365-5.30%
E
Sell
3/6/2025Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D- on 3/6/2025 due to a decline in the growth index, total return index and valuation index. EBIT declined 35.61% from $24.8M to $15.97M.
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D- on 3/6/2025 due to a decline in the growth index, total return index and valuation index. EBIT declined 35.61% from $24.8M to $15.97M.
D
Sell
1/24/2025Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D- from E+ on 1/24/2025 due to an increase in the volatility index.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D- from E+ on 1/24/2025 due to an increase in the volatility index.
E
Sell
1/6/2025Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D- on 1/6/2025 due to a decline in the total return index and volatility index.
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D- on 1/6/2025 due to a decline in the total return index and volatility index.
D
Sell
11/29/2024Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D- from E+ on 11/29/2024 due to a large increase in the total return index, volatility index and valuation index.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D- from E+ on 11/29/2024 due to a large increase in the total return index, volatility index and valuation index.
E
Sell
11/14/2024Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D- on 11/14/2024 due to a major decline in the total return index, volatility index and valuation index.
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D- on 11/14/2024 due to a major decline in the total return index, volatility index and valuation index.
D
Sell
8/8/2024Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D- from E+ on 8/8/2024 due to an increase in the volatility index.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D- from E+ on 8/8/2024 due to an increase in the volatility index.
E
Sell
5/7/2024Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D- on 5/7/2024 due to a noticeable decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.073 to -$0.1125.
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D- on 5/7/2024 due to a noticeable decline in the growth index, volatility index and solvency index. Earnings per share declined from -$0.073 to -$0.1125.
D
Sell
12/26/2023Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D- from E+ on 12/26/2023 due to an increase in the volatility index.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D- from E+ on 12/26/2023 due to an increase in the volatility index.
E
Sell
12/11/2023Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D- on 12/11/2023 due to a decline in the total return index and volatility index.
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D- on 12/11/2023 due to a decline in the total return index and volatility index.
D
Sell
8/8/2023Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D- from E+ on 8/8/2023 due to a noticeable increase in the growth index, total return index and volatility index. Operating cash flow increased 77.63% from -$80.77M to -$18.07M, EBIT increased 8.24% from -$40.74M to -$37.39M, and earnings per share increased from -$0.1928 to -$0.1817.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D- from E+ on 8/8/2023 due to a noticeable increase in the growth index, total return index and volatility index. Operating cash flow increased 77.63% from -$80.77M to -$18.07M, EBIT increased 8.24% from -$40.74M to -$37.39M, and earnings per share increased from -$0.1928 to -$0.1817.
E
Sell
5/2/2023Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D- on 5/2/2023 due to a noticeable decline in the total return index, volatility index and growth index.
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D- on 5/2/2023 due to a noticeable decline in the total return index, volatility index and growth index.
D
Sell
3/14/2023Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index and valuation index. Operating cash flow declined 594.75% from -$11.63M to -$80.77M, earnings per share declined from -$0.12 to -$0.1928, and EBIT declined 22.45% from -$33.27M to -$40.74M.
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 3/14/2023 due to a decline in the growth index and valuation index. Operating cash flow declined 594.75% from -$11.63M to -$80.77M, earnings per share declined from -$0.12 to -$0.1928, and EBIT declined 22.45% from -$33.27M to -$40.74M.
D
Sell
2/23/2023Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 2/23/2023 due to an increase in the total return index and volatility index.
D
Sell
2/8/2023Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index and valuation index. Debt to equity increased from 2.3 to 3.01, and the quick ratio declined from 2.67 to 2.47.
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index and valuation index. Debt to equity increased from 2.3 to 3.01, and the quick ratio declined from 2.67 to 2.47.
D
Sell
5/16/2022Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from E+ on 05/16/2022.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D on 5/13/2022 due to a decline in the growth index, total return index and solvency index. Debt to equity increased from 1.29 to 1.66, total revenue declined 4.19% from $82.15M to $78.72M, and the quick ratio declined from 3.67 to 3.57.
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D on 5/13/2022 due to a decline in the growth index, total return index and solvency index. Debt to equity increased from 1.29 to 1.66, total revenue declined 4.19% from $82.15M to $78.72M, and the quick ratio declined from 3.67 to 3.57.
D
Sell
5/4/2022Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from E+ on 5/4/2022 due to an increase in the valuation index.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from E+ on 5/4/2022 due to an increase in the valuation index.
E
Sell
5/1/2022Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from E+ on 04/21/2022.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D on 4/20/2022 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 197.53% from -$23.7M to -$70.51M, EBIT declined 80.03% from -$39.11M to -$70.41M, and earnings per share declined from -$0.188 to -$0.2897.
Amicus Therapeutics, Inc. (FOLD) was downgraded to E+ from D on 4/20/2022 due to a noticeable decline in the total return index, growth index and volatility index. Operating cash flow declined 197.53% from -$23.7M to -$70.51M, EBIT declined 80.03% from -$39.11M to -$70.41M, and earnings per share declined from -$0.188 to -$0.2897.
D
Sell
11/11/2021Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 11/11/2021 due to an increase in the solvency index, growth index and total return index. Debt to equity declined from 1.86 to 1.05, operating cash flow increased 34.03% from -$35.92M to -$23.7M, and the quick ratio increased from 3.86 to 5.02.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 11/11/2021 due to an increase in the solvency index, growth index and total return index. Debt to equity declined from 1.86 to 1.05, operating cash flow increased 34.03% from -$35.92M to -$23.7M, and the quick ratio increased from 3.86 to 5.02.
D
Sell
11/8/2021Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 11/8/2021 due to a decline in the solvency index, volatility index and valuation index. Debt to equity increased from 1.58 to 1.86, and the quick ratio declined from 4.64 to 3.86.
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 11/8/2021 due to a decline in the solvency index, volatility index and valuation index. Debt to equity increased from 1.58 to 1.86, and the quick ratio declined from 4.64 to 3.86.
D
Sell
5/1/2020Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 5/1/2020 due to an increase in the volatility index and growth index.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 5/1/2020 due to an increase in the volatility index and growth index.
D
Sell
3/4/2020Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 3/4/2020 due to a large decline in the growth index, efficiency index and solvency index. EBIT declined 56.38% from -$56.52M to -$88.38M, net income declined 45.17% from -$61.81M to -$89.73M, and earnings per share declined from -$0.2427 to -$0.3517.
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 3/4/2020 due to a large decline in the growth index, efficiency index and solvency index. EBIT declined 56.38% from -$56.52M to -$88.38M, net income declined 45.17% from -$61.81M to -$89.73M, and earnings per share declined from -$0.2427 to -$0.3517.
D
Sell
2/18/2020Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 2/18/2020 due to an increase in the volatility index, total return index and growth index.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 2/18/2020 due to an increase in the volatility index, total return index and growth index.
D
Sell
1/30/2020Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 1/30/2020 due to a decline in the volatility index.
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 1/30/2020 due to a decline in the volatility index.
D
Sell
1/15/2020Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 1/15/2020 due to an increase in the valuation index and total return index.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 1/15/2020 due to an increase in the valuation index and total return index.
D
Sell
12/5/2019Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 12/5/2019 due to a noticeable decline in the total return index, solvency index and volatility index. The quick ratio declined from 6.75 to 5.89, and debt to equity increased from 0.25 to 0.28.
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 12/5/2019 due to a noticeable decline in the total return index, solvency index and volatility index. The quick ratio declined from 6.75 to 5.89, and debt to equity increased from 0.25 to 0.28.
D
Sell
8/20/2019Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 8/20/2019 due to a noticeable increase in the solvency index, valuation index and growth index. Earnings per share increased from -$0.5634 to -$0.3551, debt to equity declined from 0.38 to 0.25, and total revenue increased 29.62% from $34.05M to $44.13M.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 8/20/2019 due to a noticeable increase in the solvency index, valuation index and growth index. Earnings per share increased from -$0.5634 to -$0.3551, debt to equity declined from 0.38 to 0.25, and total revenue increased 29.62% from $34.05M to $44.13M.
D
Sell
3/5/2019Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 3/5/2019 due to a decline in the valuation index and efficiency index. Total capital declined 8.92% from $729.76M to $664.65M.
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 3/5/2019 due to a decline in the valuation index and efficiency index. Total capital declined 8.92% from $729.76M to $664.65M.
D
Sell
11/26/2018Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 11/26/2018 due to an increase in the valuation index.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 11/26/2018 due to an increase in the valuation index.
D
Sell
11/7/2018Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 11/7/2018 due to a noticeable decline in the total return index, efficiency index and volatility index. Net income declined 157.41% from -$61.83M to -$159.16M, and total capital declined 0.22% from $731.34M to $729.76M.
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 11/7/2018 due to a noticeable decline in the total return index, efficiency index and volatility index. Net income declined 157.41% from -$61.83M to -$159.16M, and total capital declined 0.22% from $731.34M to $729.76M.
D
Sell
5/14/2018Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 5/14/2018 due to an increase in the solvency index, efficiency index and valuation index. Total capital increased 33.07% from $517.32M to $688.39M, debt to equity declined from 0.47 to 0.32, and net income increased 27.88% from -$69.21M to -$49.92M.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 5/14/2018 due to an increase in the solvency index, efficiency index and valuation index. Total capital increased 33.07% from $517.32M to $688.39M, debt to equity declined from 0.47 to 0.32, and net income increased 27.88% from -$69.21M to -$49.92M.
D
Sell
3/8/2018Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 3/8/2018 due to a decline in the efficiency index. Total capital declined 9.45% from $571.32M to $517.32M.
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 3/8/2018 due to a decline in the efficiency index. Total capital declined 9.45% from $571.32M to $517.32M.
D
Sell
8/9/2017Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 8/9/2017 due to a major increase in the total return index and efficiency index. Net income increased 12.47% from -$54.99M to -$48.14M.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 8/9/2017 due to a major increase in the total return index and efficiency index. Net income increased 12.47% from -$54.99M to -$48.14M.
D
Sell
6/16/2017Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 6/16/2017 due to a decline in the solvency index, valuation index and efficiency index. Debt to equity increased from 0.43 to 0.5, the quick ratio declined from 2.99 to 2.57, and total capital declined 9.18% from $514.9M to $467.64M.
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 6/16/2017 due to a decline in the solvency index, valuation index and efficiency index. Debt to equity increased from 0.43 to 0.5, the quick ratio declined from 2.99 to 2.57, and total capital declined 9.18% from $514.9M to $467.64M.
D
Sell
3/6/2017Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 3/6/2017 due to a noticeable increase in the growth index, efficiency index and solvency index. Total revenue increased 33.1% from $2.13M to $2.83M, total capital increased 27.9% from $402.58M to $514.9M, and operating cash flow increased 21.75% from -$40.88M to -$31.99M.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D from D- on 3/6/2017 due to a noticeable increase in the growth index, efficiency index and solvency index. Total revenue increased 33.1% from $2.13M to $2.83M, total capital increased 27.9% from $402.58M to $514.9M, and operating cash flow increased 21.75% from -$40.88M to -$31.99M.
D
Sell
5/5/2016Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 5/5/2016 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 10.09% from $389.44M to $350.14M, and net income declined 1.85% from -$42.9M to -$43.69M.
Amicus Therapeutics, Inc. (FOLD) was downgraded to D- from D on 5/5/2016 due to a significant decline in the volatility index, total return index and efficiency index. Total capital declined 10.09% from $389.44M to $350.14M, and net income declined 1.85% from -$42.9M to -$43.69M.
D
Sell
3/3/2016Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to D from D+ on 3/3/2016 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 6.59 to 2.91.
Amicus Therapeutics, Inc. (FOLD) was downgraded to D from D+ on 3/3/2016 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 6.59 to 2.91.
D
Sell
12/17/2015Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D+ from D on 12/17/2015 due to an increase in the valuation index.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D+ from D on 12/17/2015 due to an increase in the valuation index.
D
Sell
12/2/2015Downgrade
Amicus Therapeutics, Inc. (FOLD) was downgraded to D from D+ on 12/2/2015 due to a large decline in the total return index, growth index and valuation index. Operating cash flow declined 7.15% from -$22.64M to -$21.02M.
Amicus Therapeutics, Inc. (FOLD) was downgraded to D from D+ on 12/2/2015 due to a large decline in the total return index, growth index and valuation index. Operating cash flow declined 7.15% from -$22.64M to -$21.02M.
D
Sell
10/9/2015Upgraded
Amicus Therapeutics, Inc. (FOLD) was upgraded to D+ from D on 10/9/2015 due to a significant increase in the volatility index, total return index and solvency index. The quick ratio increased from 7.08 to 21.38, and debt to equity declined from 0.14 to 0.
Amicus Therapeutics, Inc. (FOLD) was upgraded to D+ from D on 10/9/2015 due to a significant increase in the volatility index, total return index and solvency index. The quick ratio increased from 7.08 to 21.38, and debt to equity declined from 0.14 to 0.
NASDAQ
04/10/2025 2:38PM Eastern
Quotes delayed
